American University of Integrative Sciences

Novo Integrated Sciences Advised Receipt of Proceeds of RC Consulting Promissory Note Expected in 3-5 Business Days

Retrieved on: 
Monday, November 6, 2023
General Health, Health Technology, Health, Novo, RC, American University of Integrative Sciences, Monaco, Bank

Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) today announced that RC Consulting Group LLC (“RC”) has advised that the final phase for the withdrawal/payment to Novo of the unsecured 15-year $70,000,000 promissory note with RC in favor of SCP Tourbillion Monaco for a lump sum debt funding of $57,000,000, less fees and expenses, has been initiated and is expected to be completed within the next 3-5 business days.

Key Points: 
  • Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) today announced that RC Consulting Group LLC (“RC”) has advised that the final phase for the withdrawal/payment to Novo of the unsecured 15-year $70,000,000 promissory note with RC in favor of SCP Tourbillion Monaco for a lump sum debt funding of $57,000,000, less fees and expenses, has been initiated and is expected to be completed within the next 3-5 business days.

Novo Integrated Sciences Announces Reverse Stock Split

Retrieved on: 
Monday, November 6, 2023
General Health, Health, Science, Other Science, Health Technology, Reverse stock split, CUSIP, Aphria (company), American University of Integrative Sciences, Novo, Effective date, Auction

Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today announced that the Company will undertake a reverse stock split of its common stock at a ratio of 1-for-10 (the "Reverse Stock Split").

Key Points: 
  • Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today announced that the Company will undertake a reverse stock split of its common stock at a ratio of 1-for-10 (the "Reverse Stock Split").
  • The Reverse Stock Split is expected to become effective immediately after the close of trading on the Nasdaq Capital Market ("Nasdaq") on November 6, 2023 (the "Effective Date") and the Company’s common stock is expected to begin trading on Nasdaq on a Reverse Stock Split-adjusted basis on November 7, 2023, under the new CUSIP number, 67011T300.
  • We believe that by promptly addressing the uncertainty regarding our listing we will be better positioned to maximize value for our shareholders.”
    Stockholder approval for the Reverse Stock Split was obtained at the Company's annual meeting of stockholders on September 29, 2023.
  • After careful consideration in light of current market conditions, the Company's Board of Directors approved the Reverse Stock Split ratio of 1-for-10.

Novo Integrated Sciences’ Board of Directors Approves $5 Million Stock Repurchase Program

Retrieved on: 
Tuesday, October 24, 2023
General Health, Alternative Medicine, Health, Science, Other Science, American University of Integrative Sciences, Monaco, Bank, Management

Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today announced the Company’s Board of Directors has approved the repurchase of up to $5 million of the Company's outstanding common stock ("shares") from time to time in the open market at prevailing market prices or in privately negotiated transactions.

Key Points: 
  • Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today announced the Company’s Board of Directors has approved the repurchase of up to $5 million of the Company's outstanding common stock ("shares") from time to time in the open market at prevailing market prices or in privately negotiated transactions.
  • The repurchase program does not obligate the Company to acquire any particular number of shares, and the repurchase program may be discontinued at any time at the Company's discretion.
  • Robert Mattacchione, Novo’s CEO and Chairman of the Board, stated, "Today's announcement conveys our ongoing confidence in our business and dedication to enhancing stockholder value.
  • This stock repurchase program is a direct reflection of our belief that our shares are undervalued, and a demonstration of our confidence in the business and the long-term opportunity ahead."

Novo Integrated Sciences Provides Update on Certain Current Events

Retrieved on: 
Friday, October 6, 2023
Health, Hospitals, Managed Care, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Transfer, Deutsche Bank, Risk management, RC, Collateral, Goldman Sachs, Standard Chartered, Beijing Enterprises Clean Energy Group, PCAOB, Risk, Black sheep, Monetization, American University of Integrative Sciences, Letter, Professional, Monaco, Privacy, Nature, Security (finance)

Upon completion of the Collateral transfer, the Company expects to leverage the Collateral in order to obtain a significant line of credit.

Key Points: 
  • Upon completion of the Collateral transfer, the Company expects to leverage the Collateral in order to obtain a significant line of credit.
  • The line of credit would be secured solely by the Collateral, leaving the balance of the Company’s assets free and clear.
  • Upon successful monetization, the Company will advance the prescribed fee of 15% of the monetization amount to Blacksheep Trust.
  • In short order Novo Integrated Sciences Inc. will be granted the right of first draw against the coupon resulting in a more significant role for RC as it relates to ensuring a good compliance standing.

ARTBIO Announces Appointment of Nick Pullen, Ph.D., as Chief Scientific Officer

Retrieved on: 
Thursday, October 5, 2023
Partnership, Neuroscience, Senior, University, American University of Integrative Sciences, United Kingdom, Radiopharmaceutical, SLC6A19, PKU, GPCR, Cancer, ART, Therapy, Doctor of Philosophy, Immunology, Growth, Chemistry, Friedrich Miescher Institute for Biomedical Research, Research, Pharmacology, Pfizer, Roche, Patient, Pharmaceutical industry, Jñāna

CAMBRIDGE, Mass. and OSLO, Norway and LONDON and BASEL, Switzerland, Oct. 5, 2023 /PRNewswire/ -- ARTBIO, Inc. (ARTBIO), a clinical-stage radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ART), today announced the appointment of Nick Pullen, Ph.D., as Chief Scientific Officer. Dr. Pullen brings over 20 years of leadership experience in the biopharmaceutical space and has led drug discovery programs spanning multiple gene classes, modalities and indications, including oncology, neuroscience and immunology. In this role, Dr. Pullen will be responsible for overseeing all scientific research efforts to further leverage ARTBIO's scientific approach to radiopharmaceuticals and progress the company's differentiated pipeline.

Key Points: 
  • and OSLO, Norway and LONDON and BASEL, Switzerland, Oct. 5, 2023 /PRNewswire/ -- ARTBIO, Inc. (ARTBIO), a clinical-stage radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ART), today announced the appointment of Nick Pullen, Ph.D., as Chief Scientific Officer.
  • In this role, Dr. Pullen will be responsible for overseeing all scientific research efforts to further leverage ARTBIO's scientific approach to radiopharmaceuticals and progress the company's differentiated pipeline.
  • "We are pleased to welcome Nick to our team at this pivotal time for ARTBIO.
  • Nick brings a wealth of highly relevant and valuable expertise in discovery and development of innovative therapies across multiple disease areas," said Emanuele Ostuni, Ph.D., Chief Executive Officer of ARTBIO.

ARTBIO Announces Appointment of Nick Pullen, Ph.D., as Chief Scientific Officer

Retrieved on: 
Thursday, October 5, 2023
Partnership, Neuroscience, Senior, University, American University of Integrative Sciences, United Kingdom, Radiopharmaceutical, SLC6A19, PKU, GPCR, Cancer, ART, Therapy, Doctor of Philosophy, Immunology, Growth, Chemistry, Friedrich Miescher Institute for Biomedical Research, Research, Pharmacology, Pfizer, Roche, Patient, Pharmaceutical industry, Jñāna

CAMBRIDGE, Mass. and OSLO, Norway and LONDON and BASEL, Switzerland, Oct. 5, 2023 /PRNewswire/ -- ARTBIO, Inc. (ARTBIO), a clinical-stage radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ART), today announced the appointment of Nick Pullen, Ph.D., as Chief Scientific Officer. Dr. Pullen brings over 20 years of leadership experience in the biopharmaceutical space and has led drug discovery programs spanning multiple gene classes, modalities and indications, including oncology, neuroscience and immunology. In this role, Dr. Pullen will be responsible for overseeing all scientific research efforts to further leverage ARTBIO's scientific approach to radiopharmaceuticals and progress the company's differentiated pipeline.

Key Points: 
  • and OSLO, Norway and LONDON and BASEL, Switzerland, Oct. 5, 2023 /PRNewswire/ -- ARTBIO, Inc. (ARTBIO), a clinical-stage radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ART), today announced the appointment of Nick Pullen, Ph.D., as Chief Scientific Officer.
  • In this role, Dr. Pullen will be responsible for overseeing all scientific research efforts to further leverage ARTBIO's scientific approach to radiopharmaceuticals and progress the company's differentiated pipeline.
  • "We are pleased to welcome Nick to our team at this pivotal time for ARTBIO.
  • Nick brings a wealth of highly relevant and valuable expertise in discovery and development of innovative therapies across multiple disease areas," said Emanuele Ostuni, Ph.D., Chief Executive Officer of ARTBIO.

Claremont McKenna College raises nearly $1.1 billion, shattering fund-raising record for liberal arts colleges

Retrieved on: 
Monday, October 2, 2023
American University of Integrative Sciences, Globally Responsible Leadership Initiative, Claremont McKenna College, CMS, Democracy, Moody's Investors Service, Freedom, Education, Campaign, Open Academy, KDIS, CMC, Policy, Pell, History, Government, Science, Advancement, Student, SCIAC, Investment, Trustee, Faculty, Ethics, AI, Video game, Management, Pharmaceutical industry, Nursing, College

CLAREMONT, Calif., Oct. 2, 2023 /PRNewswire/ -- Claremont McKenna College (CMC) announced today that it raised nearly $1.1 billion in its Campaign for CMC: Responsible Leadership, breaking a fund-raising record among all liberal arts colleges and far exceeding its goal of $800 million. The most successful fundraising endeavor in its 75-year-plus history, Claremont McKenna is the first liberal arts college to pass $1 billion in a campaign, raising $1,076,075,164.

Key Points: 
  • CLAREMONT, Calif., Oct. 2, 2023 /PRNewswire/ -- Claremont McKenna College (CMC) announced today that it raised nearly $1.1 billion in its Campaign for CMC: Responsible Leadership , breaking a fund-raising record among all liberal arts colleges and far exceeding its goal of $800 million.
  • The most successful fundraising endeavor in its 75-year-plus history, Claremont McKenna is the first liberal arts college to pass $1 billion in a campaign, raising $1,076,075,164.
  • Claremont McKenna College raised nearly $1.1 billion, shattering a fund-raising record for liberal arts colleges
    "This result is a testament to the commitment of our CMC community," said David G. Mgrublian '82, Chair of the Claremont McKenna College Board of Trustees.
  • "This campaign embodies Claremont McKenna College's answers to the extraordinary challenges of our time," said CMC President Hiram E. Chodosh.

Novo Integrated Sciences Signs Master Collateral Transfer Agreement

Retrieved on: 
Thursday, September 28, 2023
Science, Practice Management, Telemedicine, Virtual Medicine, Research, Managed Care, Health, Health Technology, Other Health, Transfer, American University of Integrative Sciences, Black sheep, Novo, Cryptocurrency

Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today announced Novo and Blacksheep Trust have signed a One Billion Dollar Master Collateral Transfer Agreement (the “Master Agreement”) for the purpose and general use of monetization by Novo for a period of up to 15 years.

Key Points: 
  • Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today announced Novo and Blacksheep Trust have signed a One Billion Dollar Master Collateral Transfer Agreement (the “Master Agreement”) for the purpose and general use of monetization by Novo for a period of up to 15 years.
  • The One Billion Dollar collateral transfer is expected to occur in one or more transactions during the current fiscal quarter following the validation and authentication by third-party audit procedures.
  • Robert Mattacchione, Novo’s CEO and Chairman of the Board, stated, “Novo has secured its core business capital needs with previously disclosed financings and financing opportunities.
  • We expect our ability to leverage this collateral will provide us with a self-sufficient capital platform ensuring opportunistic and strategic advantage.”

Novo Integrated Sciences Provides Update on Certain Current Actions and Events

Retrieved on: 
Thursday, September 21, 2023
General Health, Health, Practice Management, Health Technology, Medical Supplies, American University of Integrative Sciences, NOT, Central District, SWAG, United Energy Group, ASAP, Future projects of the MTR, Objective, District court, Novo, Court, Security (finance)

Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today provides an update with respect to certain actions and events, as follows:

Key Points: 
  • Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today provides an update with respect to certain actions and events, as follows:
    Annual Meeting Shareholder Voting.
  • For shareholders that hold through a brokerage account, your broker should have provided you with voting instructions.
  • If not, please contact your broker ASAP to quickly receive the necessary information to cast your vote electronically.
  • The funding is expected to result in project-specific joint ventures for development of elder care and senior living community facilities in Canada.

Novo Integrated Sciences’ IoNovo for Kids Granted Registration Number and Regulatory Approval by Turkey’s Ministry of Health

Retrieved on: 
Wednesday, September 13, 2023
Alternative Medicine, Health, Consumer, Health Technology, Fitness & Nutrition, Children, Pharmaceutical, Iodine, American University of Integrative Sciences, Hair, T4, Pharmacy, Barr v. American Assn. of Political Consultants, Inc., Nail, Absorption, Sale, Cognitive development, Novo, Immune system, City, Bacteria, Virus, Skin, Dietary supplement, Kid

Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today announced that its IoNovo for Kids pure iodine oral spray has been granted a registration number and received regulatory approval by Turkey’s Ministry of Health as a dietary supplement determined to be safe, effective, of high quality, and eligible for sale in Turkey.

Key Points: 
  • Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today announced that its IoNovo for Kids pure iodine oral spray has been granted a registration number and received regulatory approval by Turkey’s Ministry of Health as a dietary supplement determined to be safe, effective, of high quality, and eligible for sale in Turkey.
  • With this registration, Novo’s two IoNovo Iodine related products have full approval for distribution and sale throughout Turkey.
  • IoNovo Iodine is directly absorbed into the bloodstream through a precise oral spray dosage without interacting with the oral micro-biome or any bacteria or viruses.
  • All of Novo’s IoNovo products are designed to be delivered via oral spray which is proven to be significantly more effective in absorption than pill or gel capsules.